Celldex Therapeutics, Inc. (CLDX) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Completion of enrollment in two global Phase 3 EMBARQ-CSU trials and multiple Phase 2 data presentations at AAAAI (Feb 27âMar 2) have ignited a ~35% short-term rally; near-term scientific disclosures can drive further spikes, making CLDX a tactically attractive, event-driven biotech trade.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Minimal Leverage ⢠Severe Cash Burn CLDX has a very strong liquidity and low-debt balance sheet, but its extremely weak revenue, persistent losses, and heavy cash burn make the operating outlook poor despite limited near-term solvency risk.
Price Behavior
Key Price Behavior Insights: ⢠Higher-base support ⢠Momentum cooled ⢠Mid-34s resistance Support Level: $31.0â$31.4 Resistance Level: $34.5 CLDX has stayed in a constructive uptrend over the last month, holding above the $31.0â$31.4 support band, but the pullback from the $34.55 peak means it needs to reclaim about $34.5 to restore stronger upside momentum.
Sentiment & News
Key News Insights: ⢠Capital Raise ⢠Phase 2 Progress ⢠Phase III Watch CLDX's recent news centers on a large stock offering to fund barzolvolimab development, alongside positive Phase 2 allergy/urticaria data and imminent Phase III milestones.
AI Summary
CLDX has shifted from a cash-stressed clinical story to a better-funded late-stage barzolvolimab platform, so the investment case now hinges on whether Phase 3 CSU data can validate a durable commercial asset before dilution and single-program clinical risk cap the rerating.
Description
Celldex Therapeutics is a biopharmaceutical company developing monoclonal and bispecific antibody therapies for inflammatory conditions and various cancers. Its clinical pipeline includes programs directed at KIT, CD40 and a bispecific combining PD-L1 blockade with CD27 costimulation, among other antibody candidates. The company maintains research and licensing relationships with academic institutions and Amgen, and is headquartered in Hampton, New Jersey, having been incorporated in 1983.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 26 | Mar 5 | CLDX | Celldex Therapeutics, Inc. | Completion of enrollment in two global Phase 3 EMBARQ-CSU trials and multiple Phase 2 data presentations at AAAAI (Feb 27âMar 2) have ignited a ~35% short-term rally; near-term scientific disclosures can drive further spikes, making CLDX a tactically attractive, event-driven biotech trade. | Closed | -4.2% |